Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

← catalyst calendar

NCT04486833 · readout ≤ 590 d

Sponsored by Genprex, Inc. (industry) · GNPX — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

158estimated

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2021-09-03

actual

When the study began enrolling

Primary completion

Mar 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2029

estimated

The whole study's end, after follow-up

First posted

2020-07-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-21

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Carcinoma, Non-Small Cell Lung

Interventions

Biological: quaratusugene ozeplasmid — also filed as Reqorsa
Drug: osimertinib — also filed as Tagrisso
Drug: Platinum-Based Chemotherapy — also filed as cisplatin, carboplatin

Primary outcomes

what the primary-completion date above is the date OF

Recommended Phase 2 Dose (RP2D) - Phase 1

measured First 21-day treatment cycle for each dose level cohort

Overall Response Rate (ORR) - Phase 2a

measured Approximately 3 months

Progression-free Survival (PFS) - Phase 2b

measured Approximately 11 months

Publications

PMID 41385873 — cited as background

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · GNPX's whole pipeline · Catalyst calendar · Every registered study · What changed